BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair, which is focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB), announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB). The data are being shared in a poster at the Society for Investigative Dermatology (SID) Annual Meeting 2022 between May 18 – 21, 2022 in Portland, Oregon … read more